Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer

Hahne, Jens C. and Kurz, Antje and Meyer, Susanne R. and Dietl, Johannes and Engel, Jorg B. and Honig, Arnd (2015) Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 291 (1). pp. 131-141. ISSN 0932-0067, 1432-0711

Full text not available from this repository. (Request a copy)

Abstract

Platinum resistance is the most crucial problem for treatment of ovarian cancer. There is a clinical need for new treatment strategies which overcome platinum resistance. Recently high level of AKT was shown to be involved in platinum resistance and furthermore in resistance against Natural-killer (NK)-cell mediated killing in ovarian cancer. Here, we investigate the ability of the PI3K/AKT inhibitor AEZS-126 alone and in combination with rapamycin to selectively target ovarian cancer cell proliferation and survival in vitro by MTT-assays and FACS based analysis. Furthermore the mechanism of cytotoxicity is analysed by FACS based assays. The NK-killing efficiency of ovarian cancer cells with and without pre-treatment with AEZS-126 was analysed. AEZS-126 showed good anti-tumour activity in in vitro models of ovarian cancer. Main mechanism of cytotoxicity seems to be necroptosis which could be abrogated by co-incubation with necrostatin-1. Furthermore pre-treatment of platinum resistant cells with AEZS-126 resulted in an increased accessibility of these tumour cells for killing by NK-cells. We demonstrated the highly efficient anti-tumour activity of AEZS-126 in in vitro models of ovarian cancer. Due to the good anti-tumour activity and the expected increase in NK-cell mediated killing even of platinum resistant tumour cells, AEZS-126 seems to be a promising candidate for clinical testing in ovarian cancer.

Item Type: Article
Uncontrolled Keywords: NEGATIVE BREAST-CANCER; NATURAL-KILLER-CELLS; PLATINUM RESISTANCE; IN-VITRO; CARCINOMA; AKT; INHIBITION; PATHWAYS; LINES; IMMUNOSURVEILLANCE; Ovarian cancer; AKT; Platinum-resistance; NK-cells
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde)
Depositing User: Dr. Gernot Deinzer
Date Deposited: 02 Aug 2019 11:15
Last Modified: 02 Aug 2019 11:15
URI: https://pred.uni-regensburg.de/id/eprint/6343

Actions (login required)

View Item View Item